Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$INCY Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$3.60 down -259.29% YoY • Reported revenue of $1.56B up 14.00% YoY • Incyte raised full-year 2026 net sales guidance to $5.21B, Opzelura to $1.1B, and Hematology and Oncology to $890M, while reaffirming guidance for all other categories.

Price since post

Full Details

Advertisement|Remove ads.